Cantor Fitzgerald Reiterates Overweight Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They presently have a $116.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 130.02% from the company’s previous close.

RARE has been the topic of several other research reports. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Wedbush lifted their price target on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. HC Wainwright lifted their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, TD Cowen lifted their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.69.

Ultragenyx Pharmaceutical Trading Down 0.2 %

Shares of Ultragenyx Pharmaceutical stock opened at $50.43 on Wednesday. The company has a market capitalization of $4.65 billion, a PE ratio of -6.91 and a beta of 0.58. Ultragenyx Pharmaceutical has a 12 month low of $34.06 and a 12 month high of $60.37. The stock’s fifty day simple moving average is $55.19 and its 200 day simple moving average is $48.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm’s revenue was up 42.3% compared to the same quarter last year. During the same quarter last year, the business posted ($2.23) EPS. Analysts predict that Ultragenyx Pharmaceutical will post -6.29 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,556 shares of company stock valued at $1,515,967. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth approximately $119,000. Swiss National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 9.1% during the third quarter. Swiss National Bank now owns 159,152 shares of the biopharmaceutical company’s stock worth $8,841,000 after acquiring an additional 13,300 shares during the period. Mutual of America Capital Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth approximately $321,000. Natixis Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 290.0% in the third quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company’s stock valued at $2,920,000 after buying an additional 39,086 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 506 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.